China
Africa
Explore chapters and articles related to this topic
Endocrine Disorders, Contraception, and Hormone Therapy during Pregnancy
Published in “Bert” Bertis Britt Little, Drugs and Pregnancy, 2022
This drug has been withdrawn from the market and is no longer available in the US. Acetohexamide administration throughout pregnancy was significantly associated with neonatal hypoglycemia (Kemball et al., 1970). Pregnant rats given acetohexamide at many times the usual human dose on days 9 and 10 had approximately 50 percent embryonic death but no abnormalities (Bariljak, 1965). The frequency of congenital anomalies was increased, other than those expected in diabetes mellitus. Chlorpropamide is a closely related drug.
A randomized study on the usefulness of an electronic outpatient hypoglycemia risk calculator for clinicians of patients with diabetes in a safety-net institution
Published in Current Medical Research and Opinion, 2020
Michael Weiner, Jonathan Cummins, Annaswamy Raji, Susan Ofner, Kristy Iglay, Evgenia Teal, Xiaochun Li, Samuel S. Engel, Kristina Knapp, Swapnil Rajpathak, Jarod Baker, Arnaub K. Chatterjee, Larry Radican
We randomized primary care clinicians who provide outpatient care at Eskenazi Health, to see, or not see, the alert tool in outpatient clinical practice, for four months. For clinicians in the intervention group, the tool was displayed for all outpatients who were 21 or more years of age and were prescribed any of the following drugs for DM: acarbose, acetohexamide, alogliptin, canagliflozin, chlorpropamide, colesevelam, dapagliflozin, exenatide, glibenclamide, glimepiride, glipizide, glyburide, insulin, linagliptin, liraglutide, meglitol, metformin, nateglinide, pioglitazone, pramlintide, repaglinide, rosiglitazone, saxagliptin, sitagliptin, tolazamide, or voglibose. During the five-month follow-up period, we assessed patients’ characteristics, prescriptions, diagnostic testing, and HG. Clinicians randomized to the control group did not see the computerized alert tool displayed for their patients while logged into the EHR.
Advances with weak affinity chromatography for fragment screening
Published in Expert Opinion on Drug Discovery, 2019
Fotios Tsopelas, Anna Tsantili-Kakoulidou
Considering the involvement of specific interactions in retention mechanism and the fact that drugs with relatively strong binding to HSA (e.g., warfarin, tolbutamide, and acetohexamide show affinities in the range of ∼105–106 M–1, while for most drugs with weaker binding the affinity goes down to ∼103–104 M–1), plasma protein-based HPAC actually conforms with the definition of Weak Affinity Chromatography (WAC). Indeed, the development of HPAC has been an important contributing factor and opened the perspective for the realization of WAC. In fact, albumin was used as model target protein to introduce WAC in high-throughput screening of compound libraries, including the study of fragments [42]. However, unlike than for relative binding estimation by HPAC, WAC employed in fragment screening, evolves a different rationale, focusing towards the identification of specific interactions of ligands with the target protein. Efficient coupling procedures for immobilizing proteins as ligands to supports [43] as well as easy access to multi-milligram amounts of proteins from chemical or biological libraries enabled further the development of the technique [44].
Home management of pediatric sulfonylurea ingestions
Published in Clinical Toxicology, 2022
Courtney Temple, Ruby Hoang, Shana Kusin
Our findings suggest that there is a subset of pediatric patients who can safely be monitored at home, and that the risk of potential delayed presentation of these patients, even if they do develop hypoglycemia, is low. Children ≤5 years who have ingested small amounts of second-generation sulfonylureas should be considered candidates for home observation with reliable caregivers able to use glucose monitoring equipment, and close SPI follow up. We continue to recommend HCF referral for cases involving any first-generation sulfonylurea (acetohexamide, chlorpropamide, tolazamide, or tolbutamide), >1 tablet, extended-release formulations, or >4 mg of glimepiride.